ARTS-HF Inclusion Criteria 1. Subjects with clinical diagnosis of WCHF and either type 2 DM with or without CKD or moderate CKD alone treated with evidence-based therapy for HF for at least 3 months prior to emergency presentation to hospital who meet all of the inclusion and presenting none of the exclusion criteria will be eligible for enrollment in the study. 2. Subjects with worsening chronic heart failure requiring emergency presentation to hospital and treatment with intravenous (IV) diuretics at hospital 3. Left ventricular ejection fraction (LVEF) ≤40% 4. BNP >400 pg/mL or NT-proBNP >1200 pg/mL Exclusion Criteria 1. Acute coronary syndrome (ACS) 2. Acute infectious disease requiring IV antibiotics 3. Subjects requiring any IV vasodilating drug (e.g. nitrates, nitroprusside), any IV natriuretic peptide (e.g. nesiritide, carperitide) within the last 24 hours prior to randomization, or any IV positive inotropic agents within the last 14 days prior to dosing with study drug LAPTOP Inclusion Criteria 1. 2. 3. NYHA Class III Be receiving appropriate medical therapy for heart failure as per ACC/AHA Guidelines for at least 3 months prior to randomization visit. Minimum of 1 prior hospital admission within the last 12 months for acute exacerbation of HF of at least 1 calendar date change duration requiring IV or invasive HF therapy. If CRT device previously implanted, the heart failure hospitalization must be ≥ 30 days after CRT implantation. Alternatively, if patients have not had a heart failure hospitalization within the prior 12 months, they must have an elevated BNP level of at least 400pg/ml or NTproBNP level of at least 1,500pg/ml within 30 days for screening visit. Exclusion Criteria 1. Have known coexisting, untreated, hemodynamically severe stenotic valve lesions, vegetations, hypertrophic cardiomyopathy with significant resting or provoked subaortic gradient, acute myocarditis, tamponade, or large pericardial effusion. 2. Severe Pulm. Di. producing frequent hospitalizations for respiratory distress or requiring home oxygen PARACHUTE Inclusion Criteria 1. BMI < 40. 2. Symptomatic ischemic heart failure (NYHA Class III or “ambulatory” Class IV) post MI in the LAD territory at least 60 days prior to enrollment. 3. 15% ≤ LVEF ≤ 35% by TTE. 4. Post LV MI structural heart dysfunction represented by LV wall motion abnormality (WMA) by TTE. Exclusion Criteria 1. Excessive wall motion abnormalities outside the anteroapical region. 2. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA). 3. End stage renal disease requiring chronic dialysis. 4. Obstructive Sleep Apnea (OSA): unless compliant on CPAP therapy or successful surgery. 5. Hemoglobin < 10 g/dl (female), < 12 g/dl (male) or Creatinine > 2.5mg/dl.